Form 4: Aadi Bioscience CEO David James Lennon Reports Stock Transactions

CEO David James Lennon of Aadi Bioscience, Inc. reports the acquisition and disposal of company stock and restricted stock units.

Summary

• David James Lennon, CEO of Aadi Bioscience, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 1, 2025, Lennon exercised restricted stock units (RSUs) to acquire 16,250 shares of common stock.
• Following this transaction, Lennon directly owns 39,119 shares of common stock.
• On March 3, 2025, Lennon sold 5,690 shares at a price of $2.35 per share to cover tax obligations related to the vesting of the RSUs.
• After the sale, Lennon directly owns 33,429 shares of common stock.
• Lennon also holds 48,750 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in the biopharmaceutical industry. It provides transparency into the executive's holdings and transactions in the company's stock.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies, particularly in the biopharmaceutical sector.
• Similar filings are regularly made by executives at companies like Pfizer, Amgen, and Johnson & Johnson, reflecting their individual investment decisions and compensation structures.
• The size and frequency of these transactions can vary widely based on the executive's role, compensation package, and personal financial planning.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in the number of shares held by a key executive.
• The sale of shares to cover tax obligations is a common practice and is unlikely to significantly affect the company's stock price.

Key Dates